Research

Laws of Nature Predict Cancer Evolution

Cancers evolve over time in patterns governed by the same natural laws that drive physical and chemical processes as diverse as the flow of rivers or the brightness of stars, a new study reports. Researchers believe that in the future, they could predict how a cancer will grow and develop by applying natural laws to single genetic snapshots taken from a cancer.

The intriguing research raises the possibility that doctors could take clinical decisions on how an individual patient's cancer will change, and what treatments should be used, by applying mathematical formulas to tumour biopsies.

Scientists at The Institute of Cancer Research, London, and Queen Mary University of London (QMUL), used a wealth of data - generated from more than 900 tumours of 14 different types - to show that many cancers evolve in particular patterns that can be predicted.

The study, published in Nature Genetics (Monday), was funded by a donation to The Institute of Cancer Research by Chris Rokos and by organisations including the Wellcome Trust, Cancer Research UK and the Medical Research Council.

Many cancer types, such as bowel, stomach and some lung cancers, closely followed a path set out by a theoretical model describing the accumulation and spread of genetic mutations during a single rapid expansion.

The model, created by the research team, predicted that in many tumours, all important cancer genes are already present at the beginning of tumour growth, and new mutations inside the tumour are essentially 'passengers', with no additional effect.

The team showed that these passenger mutations would accumulate following a so-called 1/f power-law distribution. This pattern is found through nature in a variety of physical, chemical and biological systems including the flow of the River Nile and the luminosity of stars - and even helps to govern the financial market.

The model was less good at predicting the path of some other cancers, such as brain and pancreatic tumours, suggesting that in these cases natural selection - driven by pressures on resources and space - might play a greater role in the spread of mutations.

But in the future, the development of these types of cancers could also be predicted using more elaborate mathematical models, the scientists said. The next step in their research is to determine how the new predictive features they can measure - such as the speed of emergence of aggressive or drug-resistant mutations - map to outcomes for patients over time.

This new analysis of cancer data potentially has important clinical implications - providing a new way to distinguish mutations that should be targeted with treatment, versus 'passenger' mutations that may have no effect on cancer cell growth.

Study co-leader Dr Andrea Sottoriva, Chris Rokos Fellow in Evolution and Cancer at The Institute of Cancer Research, London, said: "Our study shows that the spread of mutations through a cancer follows natural laws - and is therefore theoretically predictable, just as we can predict the movement of celestial bodies or the weather.

"This predictability means that the vast amount of genetic data we can generate from tumour biopsies could tell us how a given cancer will develop over time - which mutations will come to drive it into more aggressive disease, when they will emerge, and which drugs are best to treat them. Like in a game of chess, the aim is anticipating the next move of the adversary, to ultimately win the game."

Study co-leader Dr Trevor Graham, head of the Evolution and Cancer laboratory at the Barts Cancer Institute at QMUL, said: "We often think of cancers as being the chaotic and uncontrolled growth of cells within the body. But counter to this intuition, our study shows how cancer evolution is in fact often highly ordered and can even be explained by a straightforward mathematical rule.

"This rule is important because it hugely simplifies our view of how cancers evolve. Now that we know the rule, we can attempt to bend it in our favour to improve patient outcomes."

Dr Kat Arney, Cancer Research UK's Science Information Manager, said: "Research like this is enabling scientists to anticipate how different cancers evolve in the body. If doctors were able to reliably predict how cancers change with time, it could help them choose the most effective treatments for each patient. Advances in DNA sequencing technology mean that we're now able to track how individual tumours change over time at the deepest genetic level."

The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes.

Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden Hospital and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.

The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.

The ICR's mission is to make the discoveries that defeat cancer.

Queen Mary University of London (QMUL) is one of the UK's leading universities, and one of the largest institutions in the University of London, with 20,260 students from more than 150 countries.

A member of the Russell Group, we work across the humanities and social sciences, medicine and dentistry, and science and engineering, with inspirational teaching directly informed by our research - in the most recent national assessment of the quality of research, we were placed ninth in the UK (REF 2014).

We also offer something no other university can: a stunning self-contained residential campus in London's East End. As well as our home at Mile End, we have campuses at Whitechapel, Charterhouse Square and West Smithfield dedicated to the study of medicine, and a base for legal studies at Lincoln's Inn Fields.

We have a rich history in London with roots in Europe's first public hospital, St Barts; England's first medical school, The London; one of the first colleges to provide higher education to women, Westfield College; and the Victorian philanthropic project, the People's Palace based at Mile End.

QMUL has an annual turnover of £350m, a research income worth £100m, and generates employment and output worth £700m to the UK economy each year.

Most Popular Now

All in One: Maximum Interoperabilit…

The Hospital Universitario Central de Asturias (HUCA) presented their success story on healthcare information system integration at the Cerner Collaboration Forum in Lond...

Read more

Weighing the Pros and Cons of Menta…

"There's an app for that." The phrase is so ubiquitous it's a meme, and trademarked by Apple Inc. In fact there are more than 165,000 mobile applications available for he...

Read more

The Entrepreneurial Village for Eur…

8 - 10 June 2016, Amsterdam, The Netherlands. The Entrepreneurial Village at eHealth Week 2016 will give you the opportunity to meet and connect with the highest profile...

Read more

Data Analytics for Unstructured Cli…

Clinical case notes are vital to delivering high-quality, coordinated patient care and optimising resources across the health economy. Yet case notes are unstructured and...

Read more

Open Call SC1-PM-07-2017: Promoting…

Proposals should develop population-oriented primary prevention interventions to promote mental well-being of young people and assess them for their effectiveness. The ...

Read more

Merck Brings International Start-Up…

Merck, a leading science and technology company, has announced the participants for its Accelerator Programs in Darmstadt and Nairobi. Almost 200 highly competitive appli...

Read more

Visbion Adds New IHE Profile Suppor…

The Europe Connectathon has been hosted by Bochum this year and Visbion have had a successful week in Germany. The team have spent a busy and productive week, alongside o...

Read more

A Future without Desktops - Address…

Opinion Article by Matthew Kybert, Systems Development & Integration Manager at The Hillingdon Hospitals NHS Foundation Trust. When clinicians in Hillingdon became the f...

Read more

IMS MAXIMS Successfully Awarded a P…

IMS MAXIMS has been awarded a place on the Crown Commercial Service (CCS) new Digital Outcomes and Specialists (DOS) Framework. The DOS Framework is one of three compleme...

Read more

Online Therapy Effective at Treatin…

Doctors from the University of Pittsburgh showed that providing an online computerized cognitive behavioral therapy (CCBT) program both alone and in combination with Inte...

Read more

Evar Guidance Engine Software Makes…

At the Charing Cross Congress in London, Siemens Healthcare presents the Evar Guidance Engine software application package to support minimally invasive treatment of aort...

Read more

Doctors 2.0 & YOU 2016

26 - 27 May, Paris, France. Doctors 2.0 & YOU, the International Digital Health Congress that offers to every health professionals the opportunity to understand how to u...

Read more

Digest Newsletter

Subscribe to our weekly Newsletter and stay updated on the latest eHealth News. Subscribe now, it's free!
© eHealthNews.eu 2006 - 2016